Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanasios D Anastasilakis

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Calcified Tissue International|February 12, 2026
Bone Adverse Events in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Comprehensive Review of the Literature from the Clinical Action Group of the European Calcified Tissue SocietyStella D'Oronzo, Anda Mihaela Naciu, Maria P Yavropoulou, et al.
European Journal of Endocrinology|May 5, 2026
Magnesium as an Endocrine Modulator: Physiological Roles, Clinical Evidence, and Therapeutic PerspectivesAndrea Palermo, Anda Mihaela Naciu, Guido Zavatta, et al.
Endocrine|May 23, 2023
Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control studyAthanasios D Anastasilakis, Stergios A Polyzos, Matthaios Savvidis, et al.
Calcified Tissue International|February 14, 2025
Basic and Clinical Scientists Working Together-Do We Make the Best of Both Worlds?Willem F Lems, Athanasios D Anastasilakis, Christina Møller Andreasen, et al.
Hormones (Athens, Greece)|November 24, 2018
Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatmentStergios A Polyzos, Jannis Kountouras, Athanasios D Anastasilakis, et al.
Metabolism: Clinical and Experimental|July 23, 2017
Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracyAthanasios D Anastasilakis, Dimitrios Koulaxis, Nikoleta Kefala, et al.
Cytokine|October 9, 2012
Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartumAthina Gkiomisi, Kali G Makedou, Athanasios D Anastasilakis, et al.
Journal of Musculoskeletal & Neuronal Interactions|September 3, 2019
Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone massAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
European Journal of Endocrinology|February 2, 2011
Serum vaspin levels in normal pregnancy in comparison with non-pregnant womenAthina Giomisi, Anargyros Kourtis, Konstantinos A Toulis, et al.
The Journal of Clinical Endocrinology and Metabolism|May 12, 2021
The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its DiscontinuationPolyzois Makras, Natasha M Appelman-Dijkstra, Socrates E Papapoulos, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Calcified Tissue International|February 12, 2026
Bone Adverse Events in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Comprehensive Review of the Literature from the Clinical Action Group of the European Calcified Tissue SocietyStella D'Oronzo, Anda Mihaela Naciu, Maria P Yavropoulou, et al.
European Journal of Endocrinology|May 5, 2026
Magnesium as an Endocrine Modulator: Physiological Roles, Clinical Evidence, and Therapeutic PerspectivesAndrea Palermo, Anda Mihaela Naciu, Guido Zavatta, et al.
Endocrine|May 23, 2023
Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control studyAthanasios D Anastasilakis, Stergios A Polyzos, Matthaios Savvidis, et al.
Calcified Tissue International|February 14, 2025
Basic and Clinical Scientists Working Together-Do We Make the Best of Both Worlds?Willem F Lems, Athanasios D Anastasilakis, Christina Møller Andreasen, et al.
Hormones (Athens, Greece)|November 24, 2018
Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatmentStergios A Polyzos, Jannis Kountouras, Athanasios D Anastasilakis, et al.
Metabolism: Clinical and Experimental|July 23, 2017
Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracyAthanasios D Anastasilakis, Dimitrios Koulaxis, Nikoleta Kefala, et al.
Cytokine|October 9, 2012
Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartumAthina Gkiomisi, Kali G Makedou, Athanasios D Anastasilakis, et al.
Journal of Musculoskeletal & Neuronal Interactions|September 3, 2019
Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone massAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
European Journal of Endocrinology|February 2, 2011
Serum vaspin levels in normal pregnancy in comparison with non-pregnant womenAthina Giomisi, Anargyros Kourtis, Konstantinos A Toulis, et al.
The Journal of Clinical Endocrinology and Metabolism|May 12, 2021
The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its DiscontinuationPolyzois Makras, Natasha M Appelman-Dijkstra, Socrates E Papapoulos, et al.
Pageof 16